We don't have enough funding to do all of the work we could do. We're working in a very small environment now. We're working in children's hospitals across the country on very specific targeted therapies, we're looking at reactions that have been in existence for a long time that cause a lot of morbidity and mortality, and we're trying to solve these problems one patient and one drug at a time. We need more funding and we need to expand the work that we're doing further.
I had a very positive meeting with Health Canada about progressive licensing in the middle of March. We spent three hours together talking a little bit about what opportunity this new framework would present for these kinds of issues, in terms of improving surveillance and improving our ability to produce safer drugs. I think the framework provides an opportunity.
The question now is whether we seize that opportunity and actually make safer drugs for Canadians and the rest of the world. I believe that's what Canada actually can provide.